Drug location

Figure 6.20 Plot of qo vs. 1/0, for the experimental data of Table 6.1 classified in Class II. The curves denote 90% absorption for two particle sizes (from left to right 10 and 25 pm) assigning Pe// = 2 x lCP2cmmin 1, which corresponds [170] to the mean, Papp = 1.68 x 10 5cms 1 of the Caco-2 permeability values of the data [90]. Drugs located above the curves are fully absorbed (Fa > 0.90) Class II drugs. Key (solubility values in) (A) buffer, pH 5.0 (B) fed state simulated intestinal fluid, pH 5.0.

The compounds shown here are widely used in medicine. Ampicillin is an antibiotic, and simvastatin is a cholesterol-lowering drug. Locate the chirality centers in each. 

In addition to variable chemical stabiUty the carbapenems are susceptible to P-lactam cleavage by a dehydropeptidase en2yme (DHP-I) located on the bmsh borders of the kidney (53). Clinically, MK 0787 (18) is used with an inhibitor of this en2yme, cil a sta tin [78852-98-9] (MK 0791) (34), 16 26 2 5 dramatic effect not only on the urinary recovery of the drug, but also reduces any nephrotoxic potential (52) (see Enzyme... 

In the food production and OTC (Over the Counter) Drug industries, like milk, soups, cough syrup, and juices, outside balanced seals are quite popular. Their design permits easy cleaning of the equipment without pump disassembly. These seals are prominent in the chemical processing industry because all metal components in the seal are located outside the fluid. This avoids problems of galvanic eorro.sion. 

The modification and enhancement of biological activity of drugs and hormones by fluorination represent one of the most fruitful recent developments in medicinal chemistry. Its first successes and most interesting subsequent developments were in the steroid field. Almost every new technique of introducing fluorine into organic compounds has been applied in this area and, as a result of both the gross and subtle chemical differences which steroids display at different locations of the nucleus, has produced a wealth of new chemistry. 

Most of the chiral membrane-assisted applications can be considered as a modality of liquid-liquid extraction, and will be discussed in the next section. However, it is worth mentioning here a device developed by Keurentjes et al., in which two miscible chiral liquids with opposing enantiomers of the chiral selector flow counter-currently through a column, separated by a nonmiscible liquid membrane [179]. In this case the selector molecules are located out of the liquid membrane and both enantiomers are needed. The system allows recovery of the two enantiomers of the racemic mixture to be separated. Thus, using dihexyltartrate and poly(lactic acid), the authors described the resolution of different drugs, such as norephedrine, salbu-tamol, terbutaline, ibuprofen or propranolol. 

Potency, the concentration (usually molar) of a drug that produces a defined effect. Often, potencies of agonists are defined in terms of EC50 or pECso values. The potency usually does not involve measures of maximal effect but rather only in locations along the concentration axis of dose-response curves. 

Lubiprostone, a drug used for treating obstipation, has been claimed to be an activator of C1C-2. This is based on a single paper showing activation by lubiprostone of currents thought to represent C1C-2. These currents, however, differ starkly from typical C1C-2 currents. Furthermore, C1C-2 is located in basolateral membranes of the intestine. This localization is incompatible with the hypothesis that its activation increases intestinal chloride and fluid secretion. Thus, the claim that lubiprostone is a Cl- channel activator must be subject to considerable doubt. 

Drug-Receptor Interaction. Figure 2 Relationships between affinity and efficacy with different agonist response patterns, (a) For partial agonists, differences in maximal responses between agonists relate to differences in efficacy. Differences in the location parameter of the concentration-response curve (potency) indicate differences in affinity, (b) For full agonists, differences in potency indicate differences in either affinity, efficacy or both. 

---